FDA okays Nabriva’s novel antibiotic Xenleta for pneumoniaIreland-headquartered biotech Nabriva has picked up its first product approval, getting an FDA okay for antibiotic Xenleta as Share XFDA okays Nabriva’s novel antibiotic Xenleta for pneumoniahttps://pharmaphorum.com/news/fda-okays-nabrivas-novel-antibiotic-xenleta-for-pneumonia/
AZ’s Farxiga first in class to improve outcomes in heart failureAstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class Share XAZ’s Farxiga first in class to improve outcomes in heart failurehttps://pharmaphorum.com/news/azs-farxiga-first-in-class-to-improve-outcomes-in-heart-failure/
Fallout over Zolgensma data scandal continues for NovartisNovartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the Share XFallout over Zolgensma data scandal continues for Novartishttps://pharmaphorum.com/news/fallout-over-zolgensma-data-scandal-continues-for-novartis/
Translating microbiome research into treatmentsThe human microbiome is a powerful and dynamic ecosystem of microbes that live on and within our bodies. Share XTranslating microbiome research into treatmentshttps://pharmaphorum.com/r-d/views-analysis-r-d/translating-microbiome-research-into-treatments/
Sharing success to unlock the “triple win” of joint workingThe fortunes of the NHS and the UK’s life sciences industry are intertwined, with each sector’s success or Share XSharing success to unlock the “triple win” of joint workinghttps://pharmaphorum.com/r-d/views-analysis-r-d/sharing-success-to-unlock-the-triple-win-of-joint-working/
Pharming buys rare disease drug from Novartis for $20mPharming has bought a late-stage pipeline drug aimed at a rare disease of the immune system from Novartis Share XPharming buys rare disease drug from Novartis for $20mhttps://pharmaphorum.com/news/pharming-buys-rare-disease-drug-from-novartis-for-20m/
Bringing innovative trials to the UKWe spoke with the National Institute for Health Research’s (NIHR) senior business development manager, Anjna Rising, to learn Share XBringing innovative trials to the UKhttps://pharmaphorum.com/r-d/views-analysis-r-d/bringing-innovative-trials-to-the-uk/
First effective Ebola treatment a step closer after breakthrough trialClinical trials of four experimental treatments for Ebola in the Congo have been halted early after two of Share XFirst effective Ebola treatment a step closer after breakthrough trialhttps://pharmaphorum.com/news/ebola-virus-clinical-trial-breakthrough/
US senators blast Novartis for Zolgensma data falsificationUS politicians have urged the FDA to come down hard on Novartis for failing to disclose manipulated data Share XUS senators blast Novartis for Zolgensma data falsificationhttps://pharmaphorum.com/news/us-senators-blast-novartis-for-zolgensma-data-falsification/
